First posted May, 2020, Updated August, 2021; Recruiting
CATEGORIES: Lupus Nephritis
The purpose of this Phase 2 study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).
This study is being offered at 8 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.
To Learn More Contact
Janssen at 844-434-4210 or email JNJ.CT@sylogent.com
ClinicalTrials.gov identifier (NCT number): NCT04376827